Andrew Lee, Ph.D.

Andrew Lee is a Managing Director at Northpond Ventures, specializing in biomanufacturing, life science R&D solutions, and environmental sciences, and leads Northpond’s newco incubation efforts at Stanford University. He is a board director at Ansa Biotherapeutics, Culture Biosciences, Encodia, OPT Industries, and Slingshot Biosciences, as well as a board observer at EnPlusOne Biosciences, Garuda Therapeutics, Refeyn, Scitara, and Sound Agriculture. Past board observer roles include Isolere Bio (acquired by Donaldson). Previously, Andrew was an Associate at Booz Allen Hamilton working in the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA), where he worked on the development and management of a high-risk, high-reward research funding portfolio in gene editing and synthetic biology. Earlier, he worked at Sangamo Biosciences (now Sangamo Therapeutics) and the Joint BioEnergy Institute. Andrew earned a Ph.D. in Microbiology and Immunology from Columbia University. He received a B.A. with honors in Molecular and Cell Biology, with an emphasis in biochemistry and molecular biology, from The University of California, Berkeley.